Mounjaro 15 mg Pen

Mounjaro 15 mg Pen

Description:

Mounjaro 15 mg Pen is a prescription injectable medicine used for the treatment of adults with type 2 diabetes mellitus and for medical weight management. It contains tirzepatide, the first dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, designed to improve blood sugar control and support significant weight loss when used alongside diet and exercise. This prefilled subcutaneous pen is intended for once-weekly administration under medical supervision as part of a comprehensive diabetes and obesity management plan.

Indications:

• Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• • In combination with other antidiabetic medicinal products (e.g. metformin, SGLT2 inhibitors, insulin) as prescribed by a healthcare professional.
• Weight management (weight loss and weight maintenance) in adults as an adjunct to a reduced-calorie diet and increased physical activity in patients with:
• • Body Mass Index (BMI) ≥ 30 kg/m2 (obesity), or
• • BMI ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
• Helps reduce elevated blood glucose levels (fasting and postprandial) in type 2 diabetes.
• Supports reduction of body weight and waist circumference in appropriate patients.

Active Ingredients / Key Components:

• Tirzepatide – 15 mg per 0.5 ml prefilled pen (concentration: 30 mg/ml).
• Excipients: Full excipient list (e.g. buffers, stabilizers, preservatives) is not provided in the available data. Please refer to the official package leaflet for the complete list of inactive ingredients.

Dosage & Administration / How to Use:

• Dosage must always be individualized and prescribed by a physician.
• Starting dose: 2.5 mg tirzepatide once weekly for 4 weeks.
• After 4 weeks, increase to 5 mg once weekly.
• If additional glycaemic control or weight reduction is needed, the dose may be increased in 2.5 mg increments (e.g. 7.5 mg, 10 mg, 12.5 mg, up to 15 mg) after a minimum of 4 weeks on the current dose, as directed by the doctor.
• Recommended maintenance doses: 5 mg, 10 mg or 15 mg once weekly, as determined by the treating physician.
• Maximum dose: 15 mg tirzepatide once weekly.
• Route of administration: Subcutaneous injection only.
• Inject into the abdomen, thigh, or upper arm, following your healthcare provider’s instructions.
• The dose can be administered at any time of the day, with or without food.
• Rotate injection sites with each dose to reduce the risk of lipodystrophy or skin irritation.
• If the patient is also using insulin, Mounjaro should be injected into a different injection site than insulin (never mix in the same syringe).
• If a dose is missed, follow the instructions provided by the prescribing physician or the official leaflet (information not fully available here; do not double dose without medical advice).
• Use only as directed by a healthcare professional experienced in the management of diabetes and/or obesity.

Clinical Benefits:

• Improves glycaemic control in adults with type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.
• Supports clinically significant weight loss and helps with long-term weight maintenance when combined with diet and physical activity.
• Reduces fasting and postprandial blood glucose levels, contributing to lower HbA1c.
• May help reduce cardiometabolic risk factors associated with obesity and type 2 diabetes, such as high blood pressure, dyslipidaemia, and central adiposity (when used as part of a comprehensive treatment plan).

Warnings & Contraindications:

• For adults with type 2 diabetes and/or obesity/overweight only; not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.
• Contraindicated in patients with known hypersensitivity to tirzepatide or any of the excipients.
• Use with caution in patients with a history of pancreatitis; inform your doctor immediately if you develop severe abdominal pain that may radiate to the back.
• May cause gastrointestinal adverse reactions (nausea, vomiting, diarrhoea); dose escalation should follow medical guidance to minimize these effects.
• Risk of hypoglycaemia increases when used in combination with insulin or insulin secretagogues (e.g. sulfonylureas); dose adjustment of concomitant therapy may be required.
• Limited data in patients with severe gastrointestinal disease, severe renal impairment, or severe hepatic impairment; use only under specialist supervision.
• Thyroid C-cell tumours have been observed in rodents with some incretin-based therapies; the clinical relevance to humans is unknown. Patients should report any neck mass, dysphagia, dyspnoea, or persistent hoarseness.
• Not recommended in pregnancy or breastfeeding unless clearly needed and prescribed by a specialist; weight loss treatment is generally not recommended during pregnancy.
• Consult your doctor before use if pregnant, nursing, planning pregnancy, taking other medications, or if you have medical conditions such as pancreatitis, severe gastrointestinal disease, kidney disease, liver disease, or thyroid disorders.
• Do not use in children or adolescents; safety and efficacy in patients under 18 years have not been established.
• Keep out of reach of children.
• This product is a prescription medicine and must be used only under medical supervision.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhoea, decreased appetite, constipation, abdominal pain, indigestion, belching, and injection site reactions (redness, itching, or swelling).
• Less common but important: Dehydration due to severe vomiting or diarrhoea, which may lead to kidney problems; dizziness; fatigue.
• Serious side effects (seek immediate medical attention): Signs of pancreatitis (severe, persistent abdominal pain that may radiate to the back, with or without vomiting), signs of allergic reaction (rash, itching, swelling of face, lips, tongue or throat, difficulty breathing), symptoms of severe hypoglycaemia (confusion, sweating, palpitations, tremor, visual disturbances, seizures, or loss of consciousness).
• This is not a complete list of side effects. Always read the official patient information leaflet and consult your doctor or pharmacist if you experience any unexpected symptoms.

Storage Instructions:

Store in a refrigerator at 2–8°c. Do not freeze. Protect from light by keeping the pen in the original carton until time of use. If necessary and as allowed by the official leaflet, the pen may be kept at room temperature for a limited period (exact duration not provided in the available data; refer to the package insert). Keep container tightly closed and out of the sight and reach of children. Do not use if the solution is cloudy, discoloured, or contains particles. Do not use after the expiry date stated on the packaging.

Specifications:

• Product type: Prescription injectable antidiabetic and weight management medicine.
• Active ingredient: Tirzepatide 15 mg per 0.5 ml (30 mg/ml).
• Form: Prefilled subcutaneous injection pen.
• Intended use: Once-weekly subcutaneous administration in adults with type 2 diabetes and/or obesity/overweight as indicated.
• Pack size: 4 subcutaneous pens/vials (exact presentation may vary by market; check outer carton).

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.